跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2011/10/002090
CTRI/2011/10/002090已完成未知

A RANDOMIZED, OPEN LABEL, TWO TREATMENT, FOUR PERIOD, TWO SEQUENCE, SINGLE DOSE, REPLICATED CROSSOVER, BIOEQUIVALENCE STUDY OF CAPECITABINE 500MG TABLETS OF SUN PHARMACEUTICAL INDUSTRIES LIMITED, INDIA AND XELODA (CAPECITABINE) 500MG TABLETS OF ROCHE REGISTRATION LTD., IN CANCER PATIENTS UNDER FED CONDITIONS.

Sun Pharmaceutical Industries Ltd0 个研究点目标入组 44 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
未知
状态
已完成
入组人数
44
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ba/be

入排标准

入选标准

  • •i. Patients at least 18 years or older.
  • •ii. Patients whose body surface area is less than or equal to 1.26 m2, between 1.53 to 1.66 m2, between 1.93 to 2.06 m2 dose is to be given in multiples of 500 mg tablet
  • •iii. Patients who have no evidence of underlying disease (except Dukes C colon cancer,
  • •metastatic colorectal carcinoma, metastatic breast cancer) during screening medical history and whose physical examination is performed within 21days prior to commencement of the study.
  • •iv. Patients who are taking Capecitabine as a single agent for adjuvant treatment for Dukes C
  • •colon cancer who have undergone complete resection of the primary tumor when treatment
  • •with fluoropyrimidine therapy alone is preferred.
  • •v. Patients who are taking Capecitabine as first-line treatment for metastatic colorectal
  • •carcinoma when treatment with fluoropyrimidine therapy alone is preferred.
  • •vi. Patients who are taking Capecitabine for the treatment of metastatic breast cancer resistant
  • •to both paclitaxel and an anthracycline containing chemotherapy regimen or resistant to
  • •paclitaxel and for whom further anthracycline therapy is not indicated, eg, patients who have
  • •received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents.(only
  • •capecitabine as chemotherapeutic agent).
  • •vii. Patients should not take any adjuvant chemotherapeutic agent except capecitabine
  • •throughout the study and 4 weeks before the study.
  • •viii. Patients whose life expectancy of greater than or equal to 6 months.
  • •ix. Patients having histologically proven Cancer.
  • •x. Patients having no brain metastasis.
  • •xi. Patients with Performance less than or equal to 2 on the ECOG performance scale (listed in Appendix III).
  • •xii. Patients whose screening laboratory values are within normal limits or considered by the
  • •Investigator/sub-Investigator to be of no clinical significance.
  • •xiii. The subject must sign the written consent form (subject Information and Consent Form)
  • •prior to study entry.
  • •xiv. The subject must have clinically acceptable results from the screening procedure including
  • •blood pressure, heart rate, 12 lead ECG, X-Ray, physical exam, medical history, hematology,
  • •biochemistry, urinalysis, and infection screen (Hepatitis B Antigen, Hepatitis C Antibody,
  • •HIV, VDRL/RPR)
  • •xv. Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.
  • •xvi. Female subjects
  • •of child bearing potential practicing an acceptable method of birth control for the
  • •duration of the study as judged by the investigator(s), such as condoms, foams, jellies,
  • •diaphragm, intrauterine device (IUD), or abstinence.
  • •Postmenopausal for at least 1 year.
  • •Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has
  • •been performed on the Subject).

排除标准

  • •i. Subjects with a history of clinically significant Cardiovascular, pulmonary, hepatic, renal,
  • •hematological (including leucopenia, thrombocytopenia), gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological, or psychiatric disease, in the last 12
  • •ii. Allergy or Significant history of hypersensitivity or idiosyncratic reactions to Capecitabine
  • •or any related compounds etc.
  • •iii. Cancer patients with a prior history of coronary artery disease, receiving concomitant
  • •therapy of warfarin.
  • •iv. Cancer patients with a prior history of dihydropyrimidine dehydrogenase deficiency.
  • •v. Presence of infections which reduce life expectancy.
  • •vi. Undergoing concomitant oncological treatment.
  • •vii. History of difficulty in swallowing or coming for follow up.
  • •viii. Clinically significant illness (except Dukes C colon cancer, metastatic colorectal carcinoma,
  • •metastatic breast cancer) within 4 weeks before the start of the study.
  • •ix. Females who are pregnant, breastfeeding, or are likely to become pregnant.
  • •x. Subjects with a history of alcohol, drug or substance abuse in the past 12 months.
  • •xi. Subjects who have used enzyme inducing or inhibiting drugs (like Phenytoin, Carbamazepine,
  • •Barbiturates, Gresiofulvine etc.) within 30 days of day 1 dosing of the study or
  • •any other prescription or over-the-counter medication within 14 days of day 1 dosing of the
  • •xii. Subjects who have used hormonal methods of contraception (including oral and transdermal
  • •contraceptives, injectable progesterone, progestin sub-dermal implants, progesteronereleasing
  • •IUDs, post-coital contraception methods) or hormone replacement therapy within
  • •30 days of day 1 dosing of the study.
  • •xiii. Subjects deemed uncooperative or non compliant.
  • •xiv. Smoking or consumption of any nicotine products.
  • •xv. Subjects who have consumed alcohol within 48 hours prior to day 1 dosing of the study.
  • •xvi. Subjects who have consumed xanthine-containing products (including caffeine, theobromines,
  • •etc.) within 24 hours prior to day 1 dosing of the study.
  • •xvii. Subjects who have consumed grapefruit, pomelo or grapefruit- or pomelo-containing products
  • •within 72 hours prior to day 1 dosing of the study.
  • •xviii. Subjects who have had an abnormal diet within 30 days prior to day 1 dosing of the study.
  • •xix. Subjects who have received an investigational product within the last 2 months prior to day 1
  • •dosing of the study.
  • •xx. Abnormal 12 lead ECG
  • •xxi. Subjects who have donated a total of 100 mL to 499 mL of whole blood within 30 days prior
  • •to day 1 dosing or Subjects who have donated a total of more than 499 mL of whole blood
  • •within 56 days prior to day 1 dosing of the study.
  • •xxii. Positive result to HIV, HCV, RPR and HBsAg.
  • •xxiii. Subjects who have:
  • •Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg
  • •Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg
  • •Minor deviations (2-4mm Hg) at check-in may be acceptable at the discretion of the Investigator.
  • •Pulse rate below 60/min. or above 100/min.

研究者

相似试验

尚未招募
不适用
To compare Dipeptidyl peptidase- 4 enzyme inhibition activity of Vildagliptin MR 100mg vs Vildagliptin IR 50 mg & evaluate pharmacokinetic profile under fasting condition.
CTRI/2020/08/027200ovartis India Limited
尚未招募
不适用
BIOEQUIVALENCE STUDY OF NILUTAMIDE TABLET, 150 MG WITH NILANDRON (NILUTAMIDE) TABLET, 150 MG IN METASTATIC PROSTATE CANCER PATIENTS UNDER FED CONDITION.
CTRI/2015/12/006440Stason Pharmaceutical Inc36
暂停
不适用
To monitor the safety and to assess bioequivalence of Bortezomib for injection, 3.5 mg/vial (1.3 mg/m2 dose) of Sun Pharmaceutical Industries Limited and Velcade (Bortezomib) for injection 3.5 mg/vial (1.3 mg/m2 dose) of Millennium Pharmaceuticals, in multiple myeloma patients, under fed conditions.
CTRI/2013/12/004235Sun Pharmaceutical Industries Ltd40
Unknown
1 期
Pharmacology study of brimonidine
CTRI/2016/01/006491Sun Pharma Advanced Research Company Limited24
已完成
不适用
To monitor safety and assess bioequivalence of Leuprolide Acetate 7.5 mg Depot suspension of Sun Pharmaceutical Industries Limited,India and Lupron Depot 7.5 mg depot suspension of TAP Pharmaceutical Inc., USA under fasting conditions in prostatic carcinoma patients undergoing initial therapy.
CTRI/2012/02/002436Sun Pharmaceutical Industries Ltd60